Ratings Centene Corporation

Equities

CNC

US15135B1017

Market Closed - Nyse Other stock markets 04:00:02 2024-04-25 pm EDT			5-day change	1st Jan Change
75.68 ^USD	-0.67%		+2.62%	+1.98%

Apr. 24	Molina Healthcare beats profit estimates aided by higher premiums	RE
Apr. 16	Wall St set for higher open as upbeat earnings obscure Mideast jitters	RE

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.
The company has a good ESG score relative to its sector, according to Refinitiv.

Strengths

The stock, which is currently worth 2024 to 0.29 times its sales, is clearly overvalued in comparison with peers.
The company has a low valuation given the cash flows generated by its activity.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Sales forecast by analysts have been recently revised upwards.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company does not generate enough profits, which is an alarming weak point.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Managed Healthcare

	1st Jan change	Capi.	ESG Refinitiv
CENTENE CORPORATION	+1.98%	40.75B	B-
UNITEDHEALTH GROUP INC.	-6.19%	448B	B-
ELEVANCE HEALTH, INC.	+14.45%	124B	A-
CIGNA	+18.39%	99.92B	B-
HUMANA INC.	-31.98%	38.08B	A-
MOLINA HEALTHCARE, INC.	-2.49%	21.52B	B-
ALIGNMENT HEALTHCARE, INC.	-40.07%	979M	B-
CLOVER HEALTH INVESTMENTS, CORP.	-29.63%	322M	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes